Business Context and Reporting Period
This Form 8-K filing by EyePoint Pharmaceuticals, Inc. (Eyepoint) reports a corporate governance event dated October 25, 2018. The filing details the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report focused on personnel changes rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to nine members.
- New Appointment: John Landis, Ph.D., was appointed to fill the newly created vacancy and assigned to the Science Committee, effective immediately.
- Compensation Structure: Dr. Landis will receive an annual cash retainer of $40,000 for general board duties and an additional $4,000 for Science Committee service.
- Equity Grant: Dr. Landis was granted an option to acquire 80,000 shares of common stock at an exercise price of $2.27 per share (the closing price on the grant date).
- Vesting Schedule: The stock options vest in three equal annual installments commencing on the first anniversary of the grant date (October 25, 2019).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies related to the appointment were disclosed beyond standard indemnification agreements.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 80,000 new options on potential dilution.
- Confirm the terms of the 2016 Long Term Incentive Plan referenced for the option grant.
- Review the attached press release (Exhibit 99.1) for additional context on Dr. Landis's qualifications.
- Check subsequent filings for any changes to the Board composition or compensation policies.